| SC 13G/A | 2024-03-07 | BlackRock Inc. | ALPINE IMMUNE SCIENCES, INC. | 3,026,330 | 4.6% | EDGAR |
| SC 13G/A | 2024-02-14 | Lynx1 Capital Management LP | ALPINE IMMUNE SCIENCES, INC. | 3,813,926 | 6.6% | EDGAR |
| SC 13G/A | 2024-02-14 | Cormorant Asset Management, LP | ALPINE IMMUNE SCIENCES, INC. | 2,550,000 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Paradigm Biocapital Advisors LP | ALPINE IMMUNE SCIENCES, INC. | 3,176,743 | 5.5% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | ALPINE IMMUNE SCIENCES, INC. | 5,903,234 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | GREAT POINT PARTNERS LLC | ALPINE IMMUNE SCIENCES, INC. | 3,703,433 | 6.4% | EDGAR |
| SC 13G/A | 2024-02-14 | Omega Fund VI, L.P. | ALPINE IMMUNE SCIENCES, INC. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-02 | BlackRock Inc. | ALPINE IMMUNE SCIENCES, INC. | 3,058,498 | 5.3% | EDGAR |
| SC 13D/A | 2023-12-29 | ORBIMED ADVISORS LLC | ALPINE IMMUNE SCIENCES, INC. | 2,680,496 | 4.6% | EDGAR |
| SC 13D/A | 2023-11-22 | Frazier Life Sciences VIII, L.P. | ALPINE IMMUNE SCIENCES, INC. | 2,829,366 | 4.7% | EDGAR |
| SC 13D/A | 2023-11-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | ALPINE IMMUNE SCIENCES, INC. | 6,582,380 | 11.1% | EDGAR |
| SC 13D/A | 2023-11-14 | Alpine ImmunoSciences, L.P. | ALPINE IMMUNE SCIENCES, INC. | 2,675,421 | 4.6% | EDGAR |
| SC 13D/A | 2023-11-13 | ORBIMED ADVISORS LLC | ALPINE IMMUNE SCIENCES, INC. | 4,226,843 | 7.3% | EDGAR |
| SC 13G | 2023-10-23 | Cormorant Asset Management, LP | ALPINE IMMUNE SCIENCES, INC. | 2,850,000 | - | EDGAR |
| SC 13G/A | 2023-02-14 | Lynx1 Capital Management LP | ALPINE IMMUNE SCIENCES, INC. | 3,126,173 | 6.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Avidity Partners Management LP | ALPINE IMMUNE SCIENCES, INC. | 1,888,887 | 4.0% | EDGAR |
| SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | ALPINE IMMUNE SCIENCES, INC. | 724,506 | 1.6% | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | ALPINE IMMUNE SCIENCES, INC. | 4,397,368 | 9.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Paradigm Biocapital Advisors LP | ALPINE IMMUNE SCIENCES, INC. | 2,317,634 | 5.0% | EDGAR |
| SC 13G/A | 2023-02-14 | GREAT POINT PARTNERS LLC | ALPINE IMMUNE SCIENCES, INC. | 3,637,718 | 7.9% | EDGAR |